{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-100539","form_type":"8-K","ticker":"APVO","cik":"0001671584","company_name":"Aptevo Therapeutics Inc.","filed_at":"2026-03-11T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.841165+00:00","generated_at":"2026-05-15T14:51:12.988327+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Aptevo reports 86% clinical benefit rate for mipletamig combo in frontline AML, zero CRS","bullets":["Mipletamig + venetoclax + azacitidine showed 86% clinical benefit rate (CR/CRi/PR) in 28 evaluable frontline AML patients.","79% achieved CR or CRi; 61% achieved CR; 55% of CR/CRi patients reached MRD-negative status.","No cytokine release syndrome (CRS) observed; 35% of responders had high-risk TP53 mutation.","Four patients proceeded to allogeneic stem cell transplant, a rare outcome in older/unfit patients.","Data from RAINIER Phase 1b/2 trial and completed dose expansion trial support safety and tolerability."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-100539","json":"https://secwatch.observer/filing/0001193125-26-100539.json","markdown":"https://secwatch.observer/filing/0001193125-26-100539.md","text":"https://secwatch.observer/filing/0001193125-26-100539.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1671584/000119312526100539/0001193125-26-100539-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1671584/000119312526100539/apvo-20260310.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T14:51:12.988327+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}